Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ImmunityBio enters the final stretch before its October 30 Russell rank date with the borrow market easing slightly, short sellers staying put, and a retail attention spike that adds a new dimension to an already crowded calendar.
The lending picture has shifted modestly since the October 9 note flagged a sharp tightening. Availability has recovered to 15.3% from the 10.9% low seen on October 8, meaning roughly one share remains available for every six already borrowed. That is still a tight borrow by any standard, and the 52-week minimum touched near zero earlier this year, so the pool is nowhere near loose. Cost to borrow has drifted back to 1.02%, within its recent range and well below the August spike above 2.4%. The short base itself has barely moved. Short interest is 124.1 million shares, 12.6% of free float, down just 1.4% on the week. The ORTEX short score holds at 82.4, ranking IBRX in the second percentile of the universe, meaning almost every other stock in the database has a less bearish short configuration. Bears are neither covering nor pressing.
Options positioning is mildly elevated but not alarming. The put/call ratio is 0.40, slightly above its 20-day average of 0.39, and less than one standard deviation from the mean. The 52-week high is 0.42. There is no sign of aggressive downside hedging into earnings, though the call-heavy tilt is consistent with a stock that has rallied 24% over the past month and attracted speculative interest.
The Street is uniformly bullish but the analyst data is stale. The most recent changes on record are from early June. Both HC Wainwright and BTIG reiterated Buy ratings with targets of $15 and $12 respectively. D. Boral Capital carries a $23 target, though given the stock trades at $9.80, that gap warrants caution and the June publication date means it reflects a different price level. The consensus mean target is $13.00, implying roughly 33% upside from current levels. The bull case rests on ANKTIVA's data in bladder cancer and NSCLC, a January 2027 PDUFA date for the sBLA, and potential franchise expansion. Bears point to the early commercial profile, dilution risk, and competitive pressure in the same patient populations. EPS surprise ranks in the 94th percentile, one of the few factor scores that flatters the stock. Short score rank (2nd percentile) and days-to-cover rank (5th percentile) both reflect the elevated short configuration.
The index rebalance angle has also shifted marginally since the October 10 note. ORTEX now puts the probability of a Russell 2000 deletion and Russell 1000 addition at 55%, down from the 75% cited four days ago. The stock at $9.80 is 4.3% above the Russell 1000 entry line of $9.38. The Russell 2000 exit line is $10.22, and IBRX is currently 4.3% below it. The rank date is October 30. If added to the Russell 1000, ORTEX estimates $189 million of buying flow, or 1.8 days of normal volume. The deletion from the Russell 2000 would require $513 million of selling, or 5.0 days of volume. The net flow is negative on paper. In 351 comparable Russell 2000 deletions, 80% of stocks moved in the expected direction, with a median decline of 4.3% from announcement to effective date. The trade date, if the rebalance is confirmed, is December 11. The stock needs to close above $10.22 for the Russell 2000 exit rule to flip the call.
Wikipedia and ORTEX page view data show retail attention running at a z-score of 2.3 against the stock's own 90-day history, the highest attention reading in the dataset. That matters less as a fundamental signal and more as a liquidity and volatility amplifier heading into two events in quick succession.
On earnings, the next print is November 6. The four most recent results saw average next-day moves of plus or minus 2.5%, with a five-day drift that ran as wide as plus 6.3% and minus 6.3%. The setup is not a history of big one-day explosions, but the five-day tail has been meaningful in both directions.
The October 30 rank date is now 16 days away. Whether the stock closes above or below $10.22 in the weeks ahead determines whether passive trackers face a mechanical selling program in December, and that price level, not the fundamental debate, is what to watch first.
See the live data behind this article on ORTEX.
Open IBRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
